基于液相色谱法的洛匹那韦/利托那韦血药浓度分析研究进展  

Progress on blood concentration analysis of lopinavir/litonavir based on liquid chromatography

作　　者：熊静[1] 王润月 梁健[2] 谢静[1] XIONG Jing;WANG Run-Yue;LIANG Jian;XIE Jing(School of Pharmacy,Chengdu Medical College,Sichuan Chengdu 610500,China;Chengdu Institute of Biology,Chinese Academy of Sciences,Sichuan Chengdu 610041,China)

机构地区：[1]成都医学院药学院,四川成都610500 [2]中国科学院成都生物研究所,四川成都610041

出　　处：《中国医院药学杂志》2020年第18期1998-2003,共6页Chinese Journal of Hospital Pharmacy

基　　金：四川省卫健委科研课题(编号:18PJ549);抗生素研究与再评价四川省重点实验室开放课题(编号:ARRLKF19-13)。

摘　　要：洛匹那韦/利托那韦是《新型冠状病毒感染的肺炎诊疗方案》的推荐药物。洛匹那韦/利托那韦作为特殊情况下治疗COVID-19的药物,其相关的有效性和安全性数据尚未确立,有必要开展治疗药物监测(TDM),以确保在获得良好疗效的同时避免或减轻毒副反应,并为药物毒副作用的诊断和处理提供有价值的实验室依据,将临床用药从经验模式提高到比较科学的水平。本文综述了近年来洛匹那韦/利托那韦基于液相色谱法的血药浓度测定方法研究进展,包括高效液相色谱法、液相色谱-质谱联用法、超高效液相色谱法等,以及相应的样品前处理方法,为本次COVID-19治疗药物的TDM工作提供参考。Lopinavir/ritonavir is a recommended drug for the"Pneumonia Diagnosis and Treatment Program for Novel Coronavirus Infections".As a drug for the treatment of COVID-19 under special circumstances,the relevant efficacy and safety data of lopinavir/ritonavir have not been established,and it is necessary to carry out therapeutic drug monitoring(TDM)to ensure that toxicity is avoided/alleviated while obtaining good efficacy,provide valuable laboratory basis for the diagnosis and treatment of toxic side effects of drugs,and improve clinical medication from empirical mode to a more scientific level.The article reviews the research progress in the determination of lopinavir/ritonavir plasma concentration based on liquid chromatography in recent years,including high performance liquid chromatography,liquid chromatography-mass spectrometry,ultra-high performance liquid chromatography,etc.,as well as the corresponding sample pretreatment methods,providing a reference for the TDM work of this COVID-19 therapeutic drug.

关 键 词：COVID-19 洛匹那韦 利托那韦 体内药物分析 治疗药物监测 

分 类 号：R927[医药卫生—药学]